# Thrombolex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thrombolex

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.thrombolex.com
- Total disclosed funding: $50M
- Latest round: Series A (Mar 16, 2026)
- Investors on record: 1

## About

Thrombolex Inc. is a US-based medical technology company focused on developing innovative endovascular solutions for treating thromboembolic conditions. Their flagship products utilize hybrid mechanisms to enhance blood flow restoration safely and effectively.Thrombolex Inc., founded in 2016 and headquartered in the United States, specializes in developing advanced medical devices for thromboembolic treatment. The company has secured a Series A funding round of USD 50.00 mn led by OrbiMed Advisors in March 2026, marking its first investment target. The founder's background is not specified in the available data.Thrombolex, Inc. specializes in the development of innovative endovascular catheters aimed at treating arterial and venous thromboembolic (A+VTE) conditions. The core product offerings include the BASHIR™ Family of Endovascular Catheters, which utilize a unique hybrid mechanism that combines mechanical and pharmacological therapies to restore blood flow safely and effectively. These devices, notably the BASHIR™ Plus and BASHIR™ S-B catheters, are designed to enable the targeted delivery of thrombolytics through an expandable infusion basket, facilitating both immediate clot resolution and controlled fluid infusion. The primary customer base comprises hospitals and healthcare providers specializing in interventional cardiology and vascular surgery, primarily across the United States and select markets in Europe and Asia. These products address critical medical needs by facilitating faster and more effective treatments in patients experiencing severe thromboembolic events, such as pulmonary embolism and deep vein thrombosis.Thrombolex generates revenue through direct sales of its endovascular catheter products to healthcare facilities, which engage in standard procurement practices for medical supplies. The transaction structure is primarily B2B, where hospitals and clinics purchase these devices based on their clinical needs and patient volume. The pricing strategy for the BASHIR™ family of products is aligned with industry standards for advanced medical devices, reflecting the value of their unique features and clinical efficacy. Revenue is bolstered by partnerships with medical device distributors, which facilitate broader access to these products across various healthcare markets. The company’s focus on providing innovative solutions for thromboembolic diseases positions it to capture a significant share of the medical device market related to vascular interventions.In March 2026, Thrombolex Inc. raised USD 50.00 mn in Series A funding led by OrbiMed Advisors. The funds will be utilized to expand the company's U.S. commercial infrastructure and advance clinical evidence generation across its endovascular catheter platform. The company plans to launch new product developments that enhance treatment for thromboembolic conditions, though specific product details and release dates have not been disclosed. Additionally, Thrombolex is targeting expansion into select international markets in Europe and Asia by the end of 2026.

## Funding rounds

- Series A, Mar 16, 2026, $50M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A